US 12,134,655 B2
Cancer associated antibody compositions and methods of use
Daniele Biasci, Poole (GB); Goran Rakocevic, Belgrade (RS); Berke Cagkan Toptas, Cambridge, MA (US); and Ines De Santiago Domingos De Jesus, London (GB)
Assigned to ABSCI CORPORATION, Vancouver, WA (US)
Appl. No. 17/606,246
Filed by Absci Corporation, Vancouver, WA (US)
PCT Filed Apr. 29, 2020, PCT No. PCT/US2020/030534
§ 371(c)(1), (2) Date Oct. 25, 2021,
PCT Pub. No. WO2020/223392, PCT Pub. Date Nov. 5, 2020.
Claims priority of provisional application 62/840,638, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,640, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,644, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,648, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,855, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,858, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,860, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,861, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,864, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,870, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,875, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,880, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,893, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,904, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,909, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,917, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,938, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,950, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,957, filed on Apr. 30, 2019.
Claims priority of provisional application 62/840,970, filed on Apr. 30, 2019.
Claims priority of provisional application 62/841,036, filed on Apr. 30, 2019.
Claims priority of provisional application 62/841,044, filed on Apr. 30, 2019.
Claims priority of provisional application 62/841,047, filed on Apr. 30, 2019.
Claims priority of provisional application 62/841,049, filed on Apr. 30, 2019.
Prior Publication US 2022/0204643 A1, Jun. 30, 2022
Int. Cl. C07K 16/00 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01)
CPC C07K 16/32 (2013.01) [C07K 16/30 (2013.01); C07K 2317/10 (2013.01)] 9 Claims
 
1. An antibody or antigen-binding fragment thereof capable of binding to G antigen 2A (GAGEA2) that comprises:
1. a variable heavy chain complementarity-determining region 1 (CDR-H1), a CDR-H2 and a CDR-H3, wherein:
1. the CDR-H1 comprises a reconstructed polypeptide consensus sequence set out in SEQ ID NO: 794,
2. the CDR-H2 comprises a reconstructed polypeptide consensus sequence set out in SEQ ID NO: 1336, and
3. the CDR-H3 comprises a reconstructed polypeptide consensus sequence set out in SEQ ID NO: 1878; and
2. a variable light chain complementarity-determining region 1 (CDR-L1), a CDR-L2, and a CDR-L3, wherein:
1. the CDR-L1 comprises a reconstructed polypeptide consensus sequence set out in SEQ ID NO: 1065,
2. the CDR-L2 comprises a reconstructed polypeptide consensus sequence set out in SEQ ID NO: 1607, and
3. The CDR-L3 comprises a reconstructed polypeptide consensus sequence set out in SEQ ID NO: 2149.